Skip to main content
. Author manuscript; available in PMC: 2020 Oct 21.
Published in final edited form as: Cell Rep. 2020 Jan 7;30(1):112–123.e4. doi: 10.1016/j.celrep.2019.12.014

Figure 6. Inhibition of Sirtuin1/EZH2 Axis Restores CD8 Cytotoxicity.

Figure 6.

(A) MFI from EOMES, RUNX3, and T-bet in CD8 T cells pretreated with 50 μM of EX527 (SIRT1 inhibitor) overnight by flow cytometry (healthy subjects = 7; paired t test).

(B) MFI from EOMES and RUNX3 in TALL104 CD8 T cells pretreated with 1 μM of GSK126 (EZH2 inhibitor) overnight by flow cytometry (n = 4, 3 independent experiments; paired t test).

(C) MFI from RUNX3 in CD8 T cells in patients with SLE pretreated with 1 μM of GSK126 overnight by flow cytometry (SLE = 4; paired t test).

(D and E) Percentage of IFN-γ and GZMB in CD8CD38low or CD8CD38high T cells from healthy controls (D) and from patients with SLE (E) treated with 1 μM of GSK126 overnight by flow cytometry (healthy subjects = 5, shown in closed circle, SLE = 6, shown in opened circle; paired t test).

(F and G) Degranulation (%CD107a) of CD8CD38low or CD8CD38high T cells from healthy subjects (F) and from patients with SLE (G) treated with GSK126 overnight and stimulated with plate-coated CD3/CD28 antibodies for 5 h with GSK126 at the indicated concentration (n = 4, one-way ANOVA with multiple comparisons).